secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0001558370-25-000526
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte acquires SeQure Dx for $4.5M cash; adds gene-editing safety assessment services
--------------------------------------------------------------------------------

- Initial consideration $4.5M in cash; up to $2.5M additional contingent on revenue targets.
- SeQure reported ~$1.7M revenue and ~$6.5M loss (Jan–Nov 2024 unaudited); net assets $0.7M.
- Acquisition expected to be accretive to MaxCyte's revenue growth; expands cell/gene therapy offerings.
- SeQure specializes in on-target and off-target editing assessments for viral and non-viral modalities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/0001558370-25-000526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025000526/mxct-20250130x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer